Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Mesenchymal stem cells and secretome as modulators of neuroinflammation in neurological disorders

Yao D., Nie L., Liu X., Wu X., Tang Y., Pan C.

Narrative Review on Neuroinflammation, Immune Modulation, published in J Transl Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Transl Med (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41877113
PMCID
PMC13137692
DOI
10.1186/s12967-026-08052-x
Citations
1

Abstract (original English)

BACKGROUND: Neuroinflammation is a critical pathogenic driver in a wide spectrum of neurological disorders, contributing to significant morbidity and presenting a formidable therapeutic challenge. Among emerging regenerative approaches, mesenchymal stem cells (MSCs) have garnered significant attention for their potent capacity to modulate this detrimental immune response, offering hope for conditions ranging from acute brain injury to chronic neurodegeneration. OBJECTIVE: This review aims to comprehensively synthesize the current understanding of how MSCs and their secretome, particularly extracellular vesicles (EVs), therapeutically modulate neuroinflammation. We seek to elucidate the key molecular and cellular mechanisms of action and to critically evaluate the evidence for these therapies across various neurological disease models. EVIDENCE REVIEW: This review synthesizes the evolving literature on MSC-mediated immunomodulation, highlighting the therapeutic transition from cell replacement to secretome-based strategies. We examine pivotal studies elucidating the molecular mechanisms by which MSCs and their secretome regulate glial phenotypes and inflammatory pathways, preserve blood-brain barrier integrity, and modulate peripheral immune responses. Furthermore, we critically analyze therapeutic efficacy across preclinical models of acute and chronic neurological disorders an

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsAnimalsHumansNervous System DiseasesInflammationExtracellular VesiclesNeuroinflammatory DiseasesSecretome

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research